Middle East and Africa Oligonucleotide Synthesis Market Size (2024-2030)

The Middle East and Africa Oligonucleotide Synthesis Market was valued at USD 5.40 Billion and is projected to reach a market size of USD 13.85 Billion by the end of 2030. The market is anticipated to expand at a compound annual growth rate (CAGR) of 14.4% between 2024 and 2030.

An oligonucleotide is a single-stranded chain composed of several nucleoside units joined by phosphodiester bridges. Oligonucleotide synthesis is the chemical process of producing relatively tiny nucleic acid fragments. Synthetic oligonucleotides are widely used in therapeutics, research, and diagnostics. Oligonucleotides are used in life science research as probes and primers in DNA-based diagnostic test kits, as well as PCR and microarray reagents. These are being developed as direct treatments for a wide range of conditions, including cancer and neurological diseases such as Alzheimer's and Parkinson's. The increased use of synthesized oligos in therapeutic applications, as well as the expanding focus on personalized medications, are major factors driving the growth of the oligonucleotide synthesis market. Furthermore, the presence of improved healthcare infrastructure and increased government financing for synthetic biology and genome research boosts the market's overall growth. Similarly, other reasons such as a considerable increase in the geriatric population, advancements in purification and quality control technologies, and pharmaceutical companies' increasing use of oligonucleotides would help to cushion industry expansion.

Key Market Insights:

The global market for custom oligonucleotide synthesis is expanding rapidly, owing to the increased speed of research and development in synthetic biology. The need for high-end customized oligos is increasing, especially as synthetic oligonucleotides are used in a variety of commercial and academic research labs. This spike in demand is pushing efforts to improve quality by lowering contaminants and enhancing efficacy. Purification expenses, which account for around half of total production costs, are driving continuing research to find better ways to achieve desired results. Innovative non-chromatographic purification methods and in-house adaptations are among the approaches being investigated to tackle this challenge.

Middle East and Africa Oligonucleotide Synthesis Market Drivers:

Falling sequencing costs are propelling the oligonucleotide synthesis market.

In recent years, improvements in genomics research have resulted in a dramatic reduction in the cost of genome sequencing. NGS technology has greatly lowered the cost and speed of DNA sequencing. According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome has decreased dramatically, from over USD 5 million to under USD 1,000. Sequencing is increasingly employed in genomics research to not only build genomes and examine the genetic basis of human disorders, but also to better comprehend the complexities of reproductive medicine, cancer, and infectious diseases. As a result, the fast-lowering cost of sequencing is predicted to promote research activity, boosting the demand for oligonucleotide synthesis items and technologies throughout the forecast period.

Healthcare Infrastructure Development Installed base and New Technology penetration have influenced the growth of this market.

The Middle East and Africa oligonucleotide synthesis market report includes a thorough examination of healthcare expenditure growth for capital equipment, the installed base of various products, and the impact of technology adoption via lifeline curves. It also examines changes in healthcare regulatory settings and their impact on market dynamics. The study helps stakeholders make strategic decisions by giving insights into healthcare expenditure patterns. Furthermore, analysing technology effects using lifeline curves educates stakeholders about the rate of technological evolution and its consequences. Furthermore, evaluating healthcare regulatory developments ensures that stakeholders are aware of movements that may affect market dynamics, allowing for more informed decision-making in the Middle East and Africa oligonucleotide synthesis industry.

Middle East and Africa Oligonucleotide Synthesis Market Restraints and Challenges:

Recent trends indicate that in-house oligonucleotide development has a considerable impact on service provider revenues, with academic and research organisations driving this internal development. Biopharmaceutical businesses are increasingly choosing in-house oligonucleotide development or outsourcing contracts to streamline manufacturing operations and protect privacy. However, the market potential is hampered by limited criteria and budgetary limits that are difficult to manage, thus limiting market expansion. Furthermore, worldwide market expansion may be hampered by resource constraints, particularly in places where academic laboratories get little research support. Furthermore, some regions have a lack of market actors and labour limitations, which impedes oligonucleotide synthesis research. These variables collectively represent hurdles to the global expansion of the oligonucleotide synthesis market, emphasising the importance of strategic steps to overcome these limits and drive industry growth.

Middle East and Africa Oligonucleotide Synthesis Market Opportunities:

For several market participants in the oligonucleotide synthesis sector, developed countries such as the United States have been the most important marketplaces. However, low-penetration emerging markets are likely to grow significantly in the next years due to increased oligonucleotide demand, R&D spending, proteomics, genomics, and metabolomics research, healthcare costs, and ongoing healthcare system improvements. For the past few years, market participants in the oligonucleotide synthesis business have identified the Middle East and Africa region's growing economies—including UAE, Africa, and other members—as particularly profitable. UAE's aging population, increasing healthcare system, and burgeoning middle class are all driving a considerable increase in demand for genetic sequencing.

MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET REPORT COVERAGE:

Middle East and Africa Oligonucleotide Synthesis Market Segmentation:

Middle East and Africa Oligonucleotide Synthesis Market Segmentation By Product:

• Reagents and Consumables
• Equipment
• Synthesized Oligonucleotides
• Oligonucleotide-based Drugs

The Middle East and Africa Oligonucleotide Synthesis Market Segmented by Product, Synthesized Oligonucleotides held the largest market share last year and is poised to maintain its dominance throughout the forecast period. Several factors contribute to synthesised oligonucleotides' dominant position in the Middle East and Africa (MEA) oligonucleotide synthesis market. The region's thriving life science research and an increasing number of clinical trials are driving demand for these adaptable technologies, which are employed in a variety of applications including DNA analysis, gene editing, and potential treatments. Synthesised oligonucleotides serve an important role in aiding the current research boom by giving researchers precise and customisable sequences needed for their studies. Furthermore, their prospective therapeutic applications place them well for future demands, reinforcing their market leadership. As the demand for advanced molecular tools continues to develop in the MEA region, synthesised oligonucleotides are projected to maintain their dominance, acting as invaluable resources for academics and clinicians alike in furthering scientific understanding and medical innovation.

Middle East and Africa Oligonucleotide Synthesis Market Segmentation By Application:

• PCR
• DNA,
• RNAi
• Research
• Therapeutic

The Middle East and Africa Oligonucleotide Synthesis Market Segmented by Application, Research held the largest market share last year and is poised to maintain its dominance throughout the forecast period. The research segment is likely to maintain its lead in the Middle East and Africa oligonucleotide synthesis market due to the region's burgeoning field of life sciences research. This increase in research efforts in gene editing, drug discovery, and synthetic biology needs a consistent supply of synthesised oligonucleotides for applications such as DNA analysis and gene target development, confirming research as the key driver of this industry.

Middle East and Africa Oligonucleotide Synthesis Market Segmentation By End-User:

• Academic
• Pharmaceutical
• Biotechnology

The Middle East and Africa Oligonucleotide Synthesis Market Segmented by End User, Pharmaceutical held the largest market share last year and is poised to maintain its dominance throughout the forecast period. Pharmaceutical and biotechnology industries are focusing on developing alternative disease treatments. These firms make extensive use of oligonucleotides because they provide an effective mode of action for the treatment of a wide range of indications at relatively modest development costs. Furthermore, oligonucleotides are critical in resolving concerns concerning the most effective medication administration route. The production of oligonucleotide therapies is predicted to expand, increasing the market share of pharmaceutical and biotechnology companies across countries. Infrastructure for education and research is being built in rising economies with public and private funds. This element is predicted to increase the use of oligonucleotides in academic research centers.

Middle East and Africa Oligonucleotide Synthesis Market Segmentation By Region:

The Middle East and Africa Oligonucleotide Synthesis Market Segmented by Region, the Middle East held the largest market share last year and is poised to maintain its dominance throughout the forecast period. Several reasons are expected to keep the Middle East at the forefront of the MEA region's oligonucleotide synthesis industry. Some wealthy countries in the region, such as those in the Gulf Cooperation Council (GCC), are making significant investments in healthcare infrastructure and research programmes. This, together with an increasing emphasis on personalised medicine, increases the demand for oligonucleotide-based applications in research and, potentially, treatments. This concentrated investment and expanding attention have put the Middle East at the forefront of the MEA's oligonucleotide synthesis business.

COVID-19 Impact Analysis on the Middle East and Africa Oligonucleotide Synthesis Market:

COVID-19, the newest novel coronavirus, produces an infectious disease. Before the outbreak began in December 2019, COVID-19 was mainly unknown. It was declared a global pandemic by the World Health Organisation (WHO). Several well-known pharmaceutical and biopharmaceutical companies have stepped forward to support worldwide research endeavours by providing oligo products for developing diagnostic kits, treatments, and vaccinations against the virus. They worked with players in the oligonucleotide synthesis market. For example, Microsynth AG provides critical reagents, such as primer-probe sets, to PCR testing labs to help molecular diagnostic firms develop and validate accurate detection methods. In addition, they provided complete genome expertise to coronavirus research laboratories.

Latest Trends/ Developments:

The competitive landscape of the Middle East and Africa oligonucleotide synthesis market provides thorough information about each competitor's strategic stance. It contains detailed information such as a firm overview, financials, revenue generation, market potential, and investment in R&D. Furthermore, information on new market activities, regional presence, manufacturing locations and facilities, and production capacity provide a comprehensive picture of each company's operations in the region. Strengths and weaknesses analysis assists in determining competitive advantages and areas for improvement. Furthermore, product launch information, such as product breadth and application domination, emphasise each competitor's emphasis and market penetration tactics for the Middle East and Africa oligonucleotide synthesis market. This detailed research helps stakeholders make educated decisions and navigate the competitive landscape efficiently.

  Key Players:

1. Merck KGaA
2. Ajinomoto Co., Inc.
3. Agilent Technologies, Inc.
4. Bio-Synthesis Inc.
5. Eurofins Genomics
6. Kaneka Eurogentec S.A.
7. Genscript
8. Danaher
9. LGC Biosearch Technologies
10. Twist Bioscience